Ralf Dieter Hofheinz

Summary

Publications

  1. doi An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors
    Ralf Dieter Hofheinz
    Universitatsmedizin Mannheim, Heidelberg University, Mannheim, Germany
    Clin Cancer Res 16:4666-74. 2010
  2. doi Population-based patterns of care in the first-line treatment of patients with advanced esophagogastric adenocarcinoma in Germany
    Ralf Dieter Hofheinz
    TagesTherapieZentrum am Interdisziplinären Tumorzentrum Mannheim und III Medizinische Klinik, Universitatsmedizin Mannheim, Germany
    Onkologie 33:512-8. 2010
  3. doi Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel: the non-interventional 'QoLiTime' study
    Ralf Dieter Hofheinz
    University Hospital Mannheim, Mannheim, Germany
    BJU Int . 2016
  4. pmc Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors
    Ralf Dieter Hofheinz
    TagesTherapieZentrum am Interdisziplinären Tumorzentrum, Mannheim Universitätsmedizin, Mannheim, Germany
    Oncologist 21:1483-1491. 2016
  5. pmc Functional protease profiling with reporter peptides in serum specimens of colorectal cancer patients: demonstration of its routine diagnostic applicability
    Peter Findeisen
    Institute for Clinical Chemistry, Medical Faculty Mannheim of the University of Heidelberg, University Hospital Mannheim, Theodor Kutzer Ufer 1 3, Mannheim, Germany
    J Exp Clin Cancer Res 31:56. 2012
  6. pmc VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    Thomas Thomaidis
    I, Medical Department, Johannes Gutenberg University of Mainz, Langenbeckstr, 1, 55131 Mainz, Germany
    BMC Cancer 14:476. 2014
  7. pmc Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma
    Martina Mayr
    Department of Internal Medicine II, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
    BMC Cancer 12:587. 2012
  8. pmc Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study
    Josef Thaler
    Department of Internal Medicine IV Haematology and Oncology, Hospital Wels Grieskirchen, Wels, Austria
    BMC Cancer 12:438. 2012
  9. pmc Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer
    R D Hofheinz
    TagesTherapieZentrum TTZ, Interdisciplinary Tumour Centre, University Hospital Mannheim, University of Heidelberg, Theodor Kutzer Ufer 1 3, Haus 9, Mannheim 68167, Germany
    Br J Cancer 107:1678-83. 2012
  10. doi Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial
    Ralf Dieter Hofheinz
    University Hospital Mannheim, University of Heidelberg, Mannheim, Germany
    Lancet Oncol 13:579-88. 2012

Collaborators

Detail Information

Publications52

  1. doi An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors
    Ralf Dieter Hofheinz
    Universitatsmedizin Mannheim, Heidelberg University, Mannheim, Germany
    Clin Cancer Res 16:4666-74. 2010
    ..Secondary objectives included evaluation of safety, efficacy, and pharmacokinetics...
  2. doi Population-based patterns of care in the first-line treatment of patients with advanced esophagogastric adenocarcinoma in Germany
    Ralf Dieter Hofheinz
    TagesTherapieZentrum am Interdisziplinären Tumorzentrum Mannheim und III Medizinische Klinik, Universitatsmedizin Mannheim, Germany
    Onkologie 33:512-8. 2010
    ..We investigated temporal trends in therapy and factors influencing treatment decisions for these patients during a 4-year period...
  3. doi Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel: the non-interventional 'QoLiTime' study
    Ralf Dieter Hofheinz
    University Hospital Mannheim, Mannheim, Germany
    BJU Int . 2016
    ..To examine health-related quality of life (QoL) in men with metastatic castration-resistant prostate cancer (mCRPC) on cabazitaxel...
  4. pmc Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors
    Ralf Dieter Hofheinz
    TagesTherapieZentrum am Interdisziplinären Tumorzentrum, Mannheim Universitätsmedizin, Mannheim, Germany
    Oncologist 21:1483-1491. 2016
    ..Accordingly, here we review published and still-emerging data, and provide practical and evidence-based recommendations and algorithms regarding the optimal prophylactic management of EGFR inhibitor-attributable skin reactions...
  5. pmc Functional protease profiling with reporter peptides in serum specimens of colorectal cancer patients: demonstration of its routine diagnostic applicability
    Peter Findeisen
    Institute for Clinical Chemistry, Medical Faculty Mannheim of the University of Heidelberg, University Hospital Mannheim, Theodor Kutzer Ufer 1 3, Mannheim, Germany
    J Exp Clin Cancer Res 31:56. 2012
    ..Here we describe a mass spectrometry-based functional proteomic profiling approach that tracks the ex-vivo degradation of a synthetic endoprotease substrate in serum specimens of colorectal tumor patients...
  6. pmc VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    Thomas Thomaidis
    I, Medical Department, Johannes Gutenberg University of Mainz, Langenbeckstr, 1, 55131 Mainz, Germany
    BMC Cancer 14:476. 2014
    ..Thus, we aimed to assess correlations of VEGFR-3 and CXCR4 expression levels with clinical outcome in a randomized phase III study of patients with oxaliplatin/leucovorin/5-FU (FLO) versus cisplatin/leucovorin/5-FU (FLP)...
  7. pmc Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma
    Martina Mayr
    Department of Internal Medicine II, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
    BMC Cancer 12:587. 2012
    ..Targeted inhibition of platelet derived growth factor receptor (PDGFR) by imatinib may influence tumor growth and amplify chemotherapeutic effects...
  8. pmc Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study
    Josef Thaler
    Department of Internal Medicine IV Haematology and Oncology, Hospital Wels Grieskirchen, Wels, Austria
    BMC Cancer 12:438. 2012
    ..Here we report additional descriptive tolerability and quality of life data from this trial...
  9. pmc Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer
    R D Hofheinz
    TagesTherapieZentrum TTZ, Interdisciplinary Tumour Centre, University Hospital Mannheim, University of Heidelberg, Theodor Kutzer Ufer 1 3, Haus 9, Mannheim 68167, Germany
    Br J Cancer 107:1678-83. 2012
    ..In the present analysis, we sought to evaluate the potential association of HFSR and survival in German patients with metastatic colorectal cancer and locally advanced rectal cancer treated with cape in clinical trials...
  10. doi Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial
    Ralf Dieter Hofheinz
    University Hospital Mannheim, University of Heidelberg, Mannheim, Germany
    Lancet Oncol 13:579-88. 2012
    ..Fluorouracil-based chemoradiotherapy is regarded as a standard perioperative treatment in locally advanced rectal cancer. We investigated the efficacy and safety of substituting fluorouracil with the oral prodrug capecitabine...
  11. ncbi Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer
    Ralf Dieter Hofheinz
    Onkologisches Zentrum, III, Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany
    Int J Radiat Oncol Biol Phys 66:1384-90. 2006
    ..To establish the feasibility and efficacy of chemotherapy with capecitabine, weekly irinotecan, cetuximab, and pelvic radiotherapy for patients with locally advanced rectal cancer...
  12. pmc Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy
    Juliana Schwaab
    III, Medizinische Klinik, Universitatsmedizin Mannheim, Theodor Kutzer Ufer 1 3, 68167 Mannheim, Germany
    BMC Cancer 11:363. 2011
    ..In search for potential prognostic molecular markers we investigated the expression of VEGFR-1, VEGFR-2 and TKTL1 in patients with LARC treated with neoadjuvant chemoradiotherapy and cetuximab...
  13. doi KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer
    Philipp Erben
    III Medizinische Klinik, Universitatsmedizin Mannheim, Universitat Heidelberg, Mannheim, Germany
    Int J Radiat Oncol Biol Phys 81:1032-8. 2011
    ..The predictive and prognostic value of the KRAS and BRAF point mutations as well as PTEN expression in patients with locally advanced rectal cancer (LARC) treated with cetuximab-based neoadjuvant chemoradiotherapy is unknown...
  14. ncbi Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study
    Ralf Dieter Hofheinz
    Onkologisches Zentrum, III Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany
    Anticancer Drugs 16:39-45. 2005
    ..Efficacy and toxicity data are comparable to 5-FU/irinotecan combinations, although the likelihood of severe diarrhea appears to be higher with capecitabine/irinotecan...
  15. doi Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study
    Manuel Barreto Miranda
    III Medizinische Klinik, Hämatologie und Onkologie, Universitatsmedizin Mannheim, Mannheim, Germany
    J Cancer Res Clin Oncol 140:829-37. 2014
    ..We conducted a multicenter phase II study to assess the toxicity and efficacy of a combination of mitomycin C (MMC) and capecitabine in pretreated patients with metastatic or locally advanced gastric cancer...
  16. doi Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    Melanie Kripp
    III Medizinische Klinik, Universitatsmedizin Mannheim, Universitat Heidelberg, Theodor Kutzer Ufer 1 3, 68167, Mannheim, Germany
    Gastric Cancer 17:181-7. 2014
    ..Using validated instruments, we prospectively assessed QOL within the randomized FLOT65+ phase II trial...
  17. doi Characteristics, treatment and prognostic factors of patients with gynaecological malignancies treated in a palliative care unit at a university hospital
    Samantha Aeckerle
    III Medizinische Klinik, Hämatologie und Onkologie, Universitatsmedizin Mannheim, Universitat Heidelberg, Germany
    Onkologie 36:642-8. 2013
    ..Limited clinical data have been published on patients suffering from advanced gynaecological malignancies treated in palliative care units, and little is known about prognostic factors...
  18. ncbi Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a phase II trial
    Senta Ulrike Gnad-Vogt
    Onkologisches Zentrum, III Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany
    Anticancer Drugs 16:435-40. 2005
    ..Its safety and good tolerability as established in the phase I trial was confirmed...
  19. ncbi Unexpected alteration of β-catenin and c-KIT expression by 5-FU and docetaxel in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro
    Claudia Umbreit
    Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty of Mannheim, University of Heidelberg, Mannheim, Germany
    Anticancer Res 33:2457-65. 2013
    ....
  20. doi mRNA expression of platelet-derived growth factor receptor-beta and C-KIT: correlation with pathologic response to cetuximab-based chemoradiotherapy in patients with rectal cancer
    Philipp Erben
    III Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Int J Radiat Oncol Biol Phys 72:1544-50. 2008
    ....
  21. doi Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status
    Nadine Lukan
    III Medizinische Klinik, Universitatsmedizin Mannheim, Mannheim, Deutschland
    Oncology 77:293-9. 2009
    ..Anal cancers universally express the epidermal growth factor receptor (EGFR) and KRAS mutations have not been reported in anal cancer thus far...
  22. ncbi Infusional 5-fluorouracil and mitomycin C: an effective regimen in the treatment of advanced gastric cancer
    Jochen Rudi
    Abteilung Innere Medizin I, Theresienkrankenhaus und St Hedwig Klinik GmbH, Mannheim, Germany
    Onkologie 28:128-32. 2005
    ..The present analysis was carried out to evaluate the safety and efficacy of 5-FU/FA in combination with 3-weekly mitomycin C (MMC) in patients with advanced gastric cancer...
  23. ncbi Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro
    Christoph Aderhold
    Department of Otorhinolaryngology Head and Neck Surgery, University Hospital Mannheim, Theodor Kutzer Ufer 1 3, 68167 Mannheim, Germany
    Anticancer Res 33:1951-61. 2013
    ....
  24. doi Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma
    Jens Kruth
    III Medizinische Klinik, Hämatologie und Onkologie, Universitatsmedizin Mannheim, Ruprecht Karls Universitat Heidelberg, Theodor Kutzer Ufer 1 3, 68167 Mannheim, Germany
    J Cancer Res Clin Oncol 136:1845-51. 2010
    ..Therefore, we have established a combination regimen of these drugs (DocMitoCape), which demonstrated preliminary activity especially in bile duct and pancreatic carcinoma...
  25. doi Cancer patients and advance directives: a survey of patients in a hematology and oncology outpatient clinic
    Elisabeth Hubert
    III Medizinische Klinik, Universitatsmedizin Mannheim, Universitat Heidelberg, Germany
    Onkologie 36:398-402. 2013
    ..3 years after the law passed, we surveyed patients with malignant diseases with regards to their views on advance directives...
  26. ncbi mMRI at 3.0 T as an Evaluation Tool of Therapeutic Response to Neoadjuvant CRT in Patients with Advanced-stage Rectal Cancer
    Ulrike I Attenberger
    Institute of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
    Anticancer Res 37:215-222. 2017
    ..To assess whether multiparametric MRI (mMRI) can serve as a tool for evaluating response to chemoradiation therapy (CRT) in advanced-stage rectal cancer...
  27. ncbi MMP9, Cyclin D1 and β-Catenin Are Useful Markers of p16-positive Squamous Cell Carcinoma in Therapeutic EGFR Inhibition In Vitro
    Claudia Umbreit
    Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
    Anticancer Res 35:3801-10. 2015
    ..The aim of the study was to investigate the expression pattern of specific markers in p16-positive SCC cells after stimulation with lapatinib and gefitinib...
  28. doi Imatinib-associated matrix metalloproteinase suppression in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro
    Claudia Umbreit
    Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Mannheim, D 68167 Mannheim, Germany
    Oncol Rep 32:668-76. 2014
    ..Extended studies and clinical trials are needed to further investigate these findings in HPV-associated HNSCC...
  29. pmc Hypofractionated image-guided breath-hold SABR (stereotactic ablative body radiotherapy) of liver metastases--clinical results
    Judit Boda-Heggemann
    Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany
    Radiat Oncol 7:92. 2012
    ..Outcome and toxicity were retrospectively evaluated in a single-institution patient cohort who had undergone ultrasound-guided breath-hold SABR...
  30. doi Metastatic esophagogastric adenocarcinoma: trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval
    Deniz Gencer
    TagesTherapieZentrum TTZ am Interdisziplinären Tumorzentrum Mannheim ITM and III Medizinische Klinik für Hämatologie und Onkologie, Universitatsmedizin Mannheim, Universitat Heidelberg, 68167 Mannheim, Germany
    J Cancer Res Clin Oncol 139:337-45. 2013
    ..Here, we sought to evaluate factors influencing treatment decisions with special focus on the implementation of HER2 testing during the first year after trastuzumab market approval in Germany...
  31. doi Combined adjuvant radiochemotherapy with IMRT/XELOX improves outcome with low renal toxicity in gastric cancer
    Judit Boda-Heggemann
    Klinik fur Strahlentherapie und Radioonkologie, Universitatsmedizin Mannheim, Universitat Heidelberg, Mannheim, Germany
    Int J Radiat Oncol Biol Phys 75:1187-95. 2009
    ..conventional three-dimensional conformal radiotherapy (3D-CRT) and standard chemotherapy in these patients while maintaining or reducing renal toxicity...
  32. doi Alpha-fetoprotein expressing metastastic adenocarcinoma of the esophago-gastric junction responding favorably to capecitabine and oxaliplatin
    Melanie Kripp
    Onkologisches Zentrum, III Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Anticancer Drugs 20:75-8. 2009
    ..He was treated with capecitabine and oxaliplatin-based combination therapy. A long-lasting major remission was observed resulting in a survival of 18.5 months...
  33. pmc Prognostic Impact of mRNA Expression Levels of HER1-4 (ERBB1-4) in Patients with Locally Advanced Rectal Cancer
    Melanie Kripp
    III Medizinische Klinik, Universitatsmedizin Mannheim, 68167 Mannheim, Germany
    Gastroenterol Res Pract 2016:3481578. 2016
    ..Conclusion. This analysis suggests a prognostic impact of both ERBB1 and MKi67 mRNA expression in LARC patients treated with capecitabine or fluorouracil-based chemoradiotherapy. ..
  34. pmc Lapatinib-induced mesenchymal-epithelial transition in squamous cell carcinoma cells correlates with unexpected alteration of β-catenin expression
    Claudia Umbreit
    Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, D 68167 Mannheim, Germany
    Oncol Lett 11:2715-2724. 2016
    ..Further studies on the mechanistic role of MET are required in order to increase the sensitivity of cancer cells to EGFR inhibitor and block the EMT process in these cells...
  35. ncbi Expression of the mutated transketolase TKTL1, a molecular marker in gastric cancer
    Wilko I Staiger
    Department of Surgery, University Hospital Mannheim, 68135 Mannheim, Germany
    Oncol Rep 16:657-61. 2006
    ..Since molecular targeted inhibition of transketolase enzyme reactions suppresses tumor growth and metastasis, TKTL1 could be a relevant target for anti-transketolase therapies in gastric cancer...
  36. doi Quality of life and symptom evaluation in daily oncology practice: a survey of 150 patients with advanced gastrointestinal tumours receiving palliative chemotherapy
    Katharina Schultheis
    TagesTherapieZentrum, Interdisziplinäres Tumorzentrum, Mannheim, Mannheim, Germany
    Onkologie 36:33-7. 2013
    ..0) using assessment tools with an emphasis on pain and depression...
  37. doi Does physical activity improve quality of life in cancer patients undergoing chemotherapy?
    Melanie Kripp
    III Medizinische Klinik, Universitatsmedizin Mannheim, Universitat Heidelberg, Mannheim, Germany
    Oncol Res Treat 38:230-6. 2015
    ..Improved cancer treatments have resulted in prolonged survival. Nevertheless, tumor symptoms and side effects still compromise physical activity and quality of life (QoL)...
  38. ncbi Two potential mechanisms of oxaliplatin-induced haemolytic anaemia in a single patient
    Ralf Dieter Hofheinz
    III Medical Clinic, University Hospital Mannheim, University of Heidelberg, Wiesbadener Strasse 7 11, 68167 Mannheim, Germany
    Cancer Chemother Pharmacol 53:276-7. 2004
    ..We report here a third patient with an immune-haematological finding favouring a bispecific mechanism (immune-complex and penicillin type) of oxaliplatin-induced haemolysis...
  39. doi Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer
    Karoline Horisberger
    Chirurgische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Anticancer Drugs 20:519-24. 2009
    ....
  40. pmc Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany
    Kirsten Merx
    TagesTherapieZentrum am Interdisziplinären Tumorzentrum Mannheim und III Medizinische Klinik, Hämatologie und Onkologie, Universitatsmedizin Mannheim, Universitat Heidelberg, 68167 Mannheim, Germany
    Gastroenterol Res Pract 2016:1028505. 2016
    ..Usage of the combination of fluoropyrimidines and cisplatin with trastuzumab declined from 67% in cohort 1 to 50% in cohort 2. ..
  41. doi Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group
    Ralf Dieter Hofheinz
    Ralf Dieter Hofheinz and Deniz Gencer, University Hospital Mannheim, Mannheim Holger Schulz, Praxis Internistische Onkologie und Hämatologie, Frechen Michael Stahl, Kliniken Essen Mitte, Essen Susanna Hegewisch Becker, Hämatologisch Onkologische Praxis Eppendorf, Hamburg Luisa Mantovani Loeffler, Onkologie, Haematologie und Palliativmedizin, Leipzig Ursula Kronawitter, Onkologische Schwerpunktpraxis, Traunstein Georg Bolz, Medizinische Klinik I, Ludwigshafen Jochem Potenberg, Waldkrankenhaus Spandau, Berlin Felix Tauchert and Salah Eddin Al Batran, Krankenhaus Nordwest, UCT University Cancer Center, Frankfurt am Main and Andreas Schneeweiss, University of Heidelberg, Heidelberg, Germany
    J Clin Oncol 33:2444-9. 2015
    ....
  42. ncbi Liposomal encapsulated anti-cancer drugs
    Ralf Dieter Hofheinz
    Onkologisches Zentrum, III Medizinische Klinik, Fakultät für Klinische Medizin Mannheim, Universitat Heidelberg, Mannheim, Germany
    Anticancer Drugs 16:691-707. 2005
    ..Meanwhile, virtually all anti-cancer drugs have been encapsulated in liposomes using different technologies. This review will summarize preclinical and clinical data of approved and exemplary emerging liposomal anti-cancer agents...
  43. doi Molecular analysis of desmoid tumors with a high-density single-nucleotide polymorphism array identifies new molecular candidate lesions
    Philipp Erben
    III Medizinische Klinik, Sarkomzentrum, ITM Interdisziplinäres Tumorzentrum, Universitatsmedizin Mannheim, Ruprecht Karls Universitat Heidelberg, Mannheim, Germany
    Onkologie 35:684-9. 2012
    ..The mutation status of the gene coding for catenin (cadherin-associated protein) beta 1 (CTNNB1) and trisomy 8 on the chromosomal level have been described to have prognostic relevance...
  44. doi Preoperative staging of rectal tumors: comparison of endorectal ultrasound, hydro-CT, and high-resolution endorectal MRI
    Dietmar J Dinter
    Institut fur Klinische Radiologie und Nuklearmedizin, Universitatsklinikum Mannheim, Mannheim, Germany
    Onkologie 31:230-5. 2008
    ..The aim of this study was to compare transrectal ultra-sound (TRUS), hydro-computed tomography (hydro-CT), and endorectal magnetic resonance imaging (MRI) in the preoperative staging of rectal cancer...
  45. pmc CoCStom trial: study protocol for a randomised trial comparing completeness of adjuvant chemotherapy after early versus late diverting stoma closure in low anterior resection for rectal cancer
    Flavius Sandra-Petrescu
    Surgical Department, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor Kutzer Ufer 1 3, 68167, Mannheim, Germany
    BMC Cancer 15:923. 2015
    ..Two randomised controlled trials have studied early stoma closure after low anterior resection in patients with rectal cancer, one of them showing that early closure around day 8 after resection is possible without increasing morbidity...
  46. doi Dose-dependent changes in renal (1)H-/(23)Na MRI after adjuvant radiochemotherapy for gastric cancer
    Stefan Haneder
    Institute of Clinical Radiology and Nuclear Medicine, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany
    Strahlenther Onkol 191:356-64. 2015
    ..Renal function in long-term gastric cancer survivors was evaluated with 3T functional magnetic resonance imaging (MRI) including diffusion-weighted imaging (DWI) and (23)Na imaging...
  47. pmc Acute small-bowel toxicity during neoadjuvant combined radiochemotherapy in locally advanced rectal cancer: determination of optimal dose-volume cut-off value predicting grade 2-3 diarrhoea
    Tina Reis
    Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany
    Radiat Oncol 10:30. 2015
    ..Aim of this study was to analyse the differences between the irradiated small-bowel volumes and the occurrence of acute diarrhea during combined radiochemotherapy for rectal cancer...
  48. doi Presentation, treatment, and analysis of prognostic factors of terminally ill patients with gastrointestinal tumors
    Deniz Gencer
    III Medizinische Klinik, Universitatsmedizin Mannheim, Universitat Heidelberg, Mannheim, Germany
    Onkologie 32:380-6. 2009
    ..Few data have been published about terminally ill patients with gastrointestinal tumors treated in palliative care units...
  49. doi Down-regulation of MMP-2 expression due to inhibition of receptor tyrosine kinases by imatinib and carboplatin in HNSCC
    Johannes D Schultz
    Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Mannheim, Mannheim, Germany
    Oncol Rep 25:1145-51. 2011
    ..Further studies are warranted, especially one keeping in mind the moderate toxicity of imatinib...
  50. doi Cancer patients and the Internet: a survey of the 'Quality of Life' Working Groups of the Arbeitsgemeinschaft für Internistische Onkologie and the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie
    Deniz Gencer
    III Medizinische Klinik für Hämatologie und Onkologie, Universitatsmedizin Mannheim, Germany
    Onkologie 34:435-40. 2011
    ..Nevertheless, numerous obstacles exist regarding the implementation of QoL assessment in the daily practice of medical oncologists. Regular, computerized or internet home-based QoL assessments could be a step forward...
  51. doi Use of Complementary and Alternative Medicine in Cancer Patients: A Prospective Questionnaire-Based Study in an Oncological Outpatient Clinic
    Julia König
    III Medizinische Klinik, Universitx00E4 tsmedizin Mannheim, Mannheim, Germany
    Oncol Res Treat 39:260-5. 2016
    ..A questionnaire-based prospective study was conducted to evaluate the current use of complementary and alternative medicine (CAM) in a hemato-oncological outpatient clinic...
  52. doi Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events
    Ralf Dieter Hofheinz
    Interdisciplinary Tumor Center Mannheim, University Hospital Mannheim, Germany
    Oncol Res Treat 38:300-8. 2015
    ..This review aims to provide guidance around prophylaxis and management of regorafenib-associated adverse events...